Last Updated: November 13, 2026

Genzyme Company Profile

« Back to Dashboard

What is the competitive landscape for GENZYME

GENZYME has eleven approved drugs.

There are seventeen US patents protecting GENZYME drugs.

Summary for Genzyme

US Patents:	17
Tradenames:	10
Ingredients:	10
NDAs:	11

Drugs and US Patents for Genzyme

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Genzyme Corp	CAPRELSA	vandetanib	TABLET;ORAL	022405-001	Apr 6, 2011		RX	Yes	No	8,067,427	⤷ Start Trial	Y			⤷ Start Trial
Genzyme Corp	WAYRILZ	rilzabrutinib	TABLET;ORAL	219685-001	Aug 29, 2025		RX	Yes	Yes	9,994,576	⤷ Start Trial	Y	Y		⤷ Start Trial
Genzyme Corp	QFITLIA	fitusiran sodium	SOLUTION;SUBCUTANEOUS	219019-002	Mar 28, 2025		RX	Yes	Yes	9,127,274	⤷ Start Trial	Y	Y		⤷ Start Trial
Genzyme Corp	QFITLIA	fitusiran sodium	SOLUTION;SUBCUTANEOUS	219019-001	Mar 28, 2025		RX	Yes	Yes	RE50996	⤷ Start Trial	Y	Y		⤷ Start Trial
Genzyme Corp	CERDELGA	eliglustat tartrate	CAPSULE;ORAL	205494-001	Aug 19, 2014	AB	RX	Yes	Yes	10,888,547	⤷ Start Trial				⤷ Start Trial
Genzyme Corp	QFITLIA	fitusiran sodium	SOLUTION;SUBCUTANEOUS	219019-002	Mar 28, 2025		RX	Yes	Yes	RE50996	⤷ Start Trial	Y	Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Genzyme

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Genzyme	RENVELA	sevelamer carbonate	FOR SUSPENSION;ORAL	022318-002	Feb 18, 2009	6,858,203	⤷ Start Trial
Genzyme Corp	CAPRELSA	vandetanib	TABLET;ORAL	022405-001	Apr 6, 2011	RE42353	⤷ Start Trial
Genzyme	RENAGEL	sevelamer hydrochloride	TABLET;ORAL	021179-002	Jul 12, 2000	6,733,780	⤷ Start Trial
Genzyme	RENAGEL	sevelamer hydrochloride	TABLET;ORAL	021179-001	Jul 12, 2000	6,509,013	⤷ Start Trial
Genzyme	RENAGEL	sevelamer hydrochloride	TABLET;ORAL	021179-001	Jul 12, 2000	7,014,846	⤷ Start Trial
Genzyme	MOZOBIL	plerixafor	SOLUTION;SUBCUTANEOUS	022311-001	Dec 15, 2008	6,987,102	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for GENZYME drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	800 mg	➤ Subscribe	2008-12-04
➤ Subscribe	Injection	1 mg/mL, 20 mL vial	➤ Subscribe	2012-02-23
➤ Subscribe	Tartrate Capsules	84mg	➤ Subscribe	2018-08-20
➤ Subscribe	Tablets	400 mg and 800 mg	➤ Subscribe	2008-05-22
➤ Subscribe	Powder for Oral Suspension	0.8 g/packet and 2.4 g/packet	➤ Subscribe	2009-12-30
➤ Subscribe	Injection	24 mg/1.2 mL vials (20 mg/mL)	➤ Subscribe	2012-12-17

International Patents for Genzyme Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Taiwan	I586663	⤷ Start Trial
Spain	2586947	⤷ Start Trial
Denmark	3386518	⤷ Start Trial
Colombia	7240361	⤷ Start Trial
Russian Federation	2754188	⤷ Start Trial
Lithuania	3386518	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Genzyme Drugs

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1409467	1590029-3	Sweden	⤷ Start Trial	PRODUCT NAME: ELIGLUSTAT, VALFRITT I FORM AV ETT FYSIOLOGISKT GODTAGBART SALT; REG. NO/DATE: EU/1/14/974 20150121
3181567	2026C/719	Belgium	⤷ Start Trial	PRODUCT NAME: RILZABRUTINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; AUTHORISATION NUMBER AND DATE: EU/1/25/1974 20251223
2371361	301031	Netherlands	⤷ Start Trial	PRODUCT NAME: PLERIXAFOR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF METAALCOMPLEX DAARVAN; REGISTRATION NO/DATE: EU/1/09/537/001 20090804
2371361	5/2020	Austria	⤷ Start Trial	PRODUCT NAME: PLERIXAFOR, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER EINES PHARMAZEUTISCH ANNEHMBAREN METALLKOMPLEXES; REGISTRATION NO/DATE: EU/1/09/537/001 20090804
1411918	132012902063874	Italy	⤷ Start Trial	PRODUCT NAME: PLERIXAFOR(MOZOBIL); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/09/537/001, 20090731
1409467	15C0036	France	⤷ Start Trial	PRODUCT NAME: ELIGLUSTAT,EVENTUELLEMENT SOUS FORME D'UN SEL PHYSIOLOGIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE: EU/1/14/974 20150119
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.